Medicine Recommendations

NICE TA676 - for treating moderate to severe rheumatoid arthritis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Treating moderately to severely active ulcerative colitis - NICE TA792

NICE TA792 - Filgotinib for treating moderately to severely active ulcerative colitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Benign Prostatic Hyperplasia

BJUI - Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia 

Chronic kidney disease in type 2 diabetes (NICE TA877)

NICE TA 877 - Finerenone for treating chronic kidney disease in type 2 diabetes

Arrhythmias

Psoriasis

Treating chronic diabetic macular oedema (NICE TA953)

NICE TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema

Fluocinolone acetonide intravitreal implant for treating recurrent noninfectious uvetitis (NICE TA590)

NICE TA 590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis

Prophylaxis of dental caries

Treatment of head and neck cancer patients who have had surgery, radiotherapy and/or chemotherapy

Treatment of Actinic Keratosis

Topical treatment of superficial pre-malignant skin lesions.

Treatment of small superficial basal-cell carcinomas in adults

Premature ejaculation

Depressive illness, Bulimia Nervosa, Obsessive Compulsive Disorder

MHRA Drug Safety Update  - Fluoxetine: possible small risk of congenital cardiac defects

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of schizophrenia and psychoses

Maintenance in schizophrenia and other psychoses

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.